The partnership shared vision is that in the future, economically sustainable and resilient health systems will be able to deliver affordable and accessible quality healthcare across Africa, while increasing access to financial products, supporting small business development and creating jobs.
To help achieve this, the partnership will implement an initial pilot in Zambia to explore and address the economic and financial barriers that currently exist in health systems across Africa. Barclays and GSK will together invest up to £7m over 3 years with the ambitious goal to reach 1 million out of the total population of 14 million people living in Zambia, by 2016.
The partnership has been designed to align with the Zambian government’s National Health plans.
Over the three years, Barclays and GSK will evenly split an investment of £7 million, comprising financial support and on the ground resource. The Partnership role is to help facilitate – GSK is working to ensure this project is locally owned and self-sustaining by collaborating with local partners. They are taking a learning approach and will be transparent about our successes and challenges. The aim of GSK is to create and test models that could be scaled into other markets in Africa.
The partnership is currently finalizing the basket of medicines that will be made available through the private sector supply chain. Five to ten of GSK’s products will be included in this basket of medicines. It is anticipated that as the program grows across the country and to other countries GSK will reach a significant return on investment through expanded reach and increased volumes of sales.
Additionally, Barclays/GSK partnership programme has been recognized by the Clinton Global Initiatives as a 2013 Commitment to Action.
|Location||Southern Africa, Zambia|
|Value||GBP 7 Million|